Which has better earnings and valuation, ABOS or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is ABOS or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Design Therapeutics N/A -33.07% -31.29%

Does the media favor ABOS or DSGN?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Design Therapeutics' score of 0.94 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SLDB or ABOS?

Solid Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is SLDB or ABOS more profitable?

Solid Biosciences' return on equity of -73.42% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media refer more to SLDB or ABOS?

In the previous week, Solid Biosciences had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Solid Biosciences' score of 0.72 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to CRMD or ABOS?

In the previous week, CorMedix and CorMedix both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat CorMedix's score of 1.26 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, CLYM or ABOS?

Climb Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is CLYM or ABOS more profitable?

Climb Bio's return on equity of -31.45% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media refer more to CLYM or ABOS?

In the previous week, Climb Bio and Climb Bio both had 2 articles in the media. Climb Bio's average media sentiment score of 1.87 equaled Acumen Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate AVTE or ABOS?

Acumen Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, AVTE or ABOS?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is AVTE or ABOS more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Acumen Pharmaceuticals N/A -123.07% -79.41%

Acumen Pharmaceuticals (ABOS) Competitors

$2.29 -0.08 (-3.38%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$2.31 +0.02 (+0.87%)

As of 06/3/2026 07:51 PM Eastern

Compare

ABOS vs. DSGN, SLDB, CRMD, CLYM, and AVTE

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Design Therapeutics (DSGN), Solid Biosciences (SLDB), CorMedix (CRMD), Climb Bio (CLYM), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Acumen Pharmaceuticals compare to Design Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Design Therapeutics' score of 0.94 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Design Therapeutics' return on equity of -33.07% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Design Therapeutics	N/A	-33.07%	-31.29%

Acumen Pharmaceuticals presently has a consensus target price of $6.67, indicating a potential upside of 191.12%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 58.05%. Given Acumen Pharmaceuticals' higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats Acumen Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Solid Biosciences' return on equity of -73.42% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

In the previous week, Solid Biosciences had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Solid Biosciences' score of 0.72 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Solid Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Solid Biosciences presently has a consensus price target of $16.82, suggesting a potential upside of 145.52%. Acumen Pharmaceuticals has a consensus price target of $6.67, suggesting a potential upside of 191.12%. Given Acumen Pharmaceuticals' higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Solid Biosciences beats Acumen Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

In the previous week, CorMedix and CorMedix both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat CorMedix's score of 1.26 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CorMedix has a net margin of 45.25% compared to Acumen Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

CorMedix has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CorMedix has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.07	$163.05M	$2.13	3.86
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

CorMedix currently has a consensus target price of $15.00, indicating a potential upside of 82.26%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

CorMedix beats Acumen Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Climb Bio's return on equity of -31.45% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 2.6% of Climb Bio shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Climb Bio presently has a consensus price target of $20.30, indicating a potential upside of 94.44%. Acumen Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Climb Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

In the previous week, Climb Bio and Climb Bio both had 2 articles in the media. Climb Bio's average media sentiment score of 1.87 equaled Acumen Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Climb Bio beats Acumen Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Acumen Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Aerovate Therapeutics' score of 0.67 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Positive
Acumen Pharmaceuticals	Very Positive

Summary

Acumen Pharmaceuticals beats Aerovate Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.18M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.23	17.78	22.39	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.97	6.63	9.84	6.72
Net Income	-$121.33M	$24.20M	$3.57B	$337.19M
7 Day Performance	-9.84%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	114.02%	45.50%	26.49%	33.10%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.6333 of 5 stars	$2.29 -3.4%	$6.67 +191.1%	+120.2%	$171.18M	N/A	N/A	20	Positive News
DSGN Design Therapeutics	2.7627 of 5 stars	$11.08 +1.0%	$16.50 +48.9%	+160.3%	$692.06M	N/A	N/A	40
SLDB Solid Biosciences	2.7909 of 5 stars	$6.81 +2.9%	$16.36 +140.3%	+95.7%	$670.44M	N/A	N/A	100	Analyst Forecast Gap Up
CRMD CorMedix	3.4752 of 5 stars	$8.27 +3.6%	$15.00 +81.4%	-34.7%	$648.78M	$311.71M	3.88	30	Positive News
CLYM Climb Bio	3.3061 of 5 stars	$11.25 +2.3%	$20.30 +80.4%	+709.3%	$644.18M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. DSGN, SLDB, CRMD, CLYM, and AVTE

How does Acumen Pharmaceuticals compare to Design Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Summary

How does Acumen Pharmaceuticals compare to CorMedix?

Summary

How does Acumen Pharmaceuticals compare to Climb Bio?

Summary

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. DSGN, SLDB, CRMD, CLYM, and AVTE

How does Acumen Pharmaceuticals compare to Design Therapeutics?

Does the media favor ABOS or DSGN?

Which has better earnings and valuation, ABOS or DSGN?

Which has more volatility & risk, ABOS or DSGN?

Do insiders and institutionals have more ownership in ABOS or DSGN?

Is ABOS or DSGN more profitable?

Do analysts recommend ABOS or DSGN?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Which has more volatility and risk, SLDB or ABOS?

Is SLDB or ABOS more profitable?

Does the media refer more to SLDB or ABOS?

Which has higher valuation & earnings, SLDB or ABOS?

Do analysts recommend SLDB or ABOS?

Do institutionals and insiders believe in SLDB or ABOS?

Summary

How does Acumen Pharmaceuticals compare to CorMedix?

Does the media refer more to CRMD or ABOS?

Is CRMD or ABOS more profitable?

Which has more risk & volatility, CRMD or ABOS?

Do insiders & institutionals have more ownership in CRMD or ABOS?

Which has preferable valuation & earnings, CRMD or ABOS?

Do analysts recommend CRMD or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Climb Bio?

Is CLYM or ABOS more profitable?

Do institutionals and insiders have more ownership in CLYM or ABOS?

Which has more risk and volatility, CLYM or ABOS?

Do analysts rate CLYM or ABOS?

Which has better valuation and earnings, CLYM or ABOS?

Does the media refer more to CLYM or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Do analysts rate AVTE or ABOS?

Is AVTE or ABOS more profitable?

Which has preferable valuation & earnings, AVTE or ABOS?

Which has more volatility & risk, AVTE or ABOS?

Do insiders & institutionals have more ownership in AVTE or ABOS?

Does the media refer more to AVTE or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools